We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
67 result(s) found, displaying 21 to 30
-
Prescription medicine registrationActive ingredients: Aflibercept.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YUFLYMA adalimumab (rch) 20 mg/0.2 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 90mg/1 mL solution for injection pre-filled syringe with safety guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 45 mg/0.5 mL solution for injection pre-filled syringe with safety guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for STEQEYMA ustekinumab 130 mg/26 mL concentrate for solution for infusion vial.
-
Prescription medicine registrationActive ingredients: Omalizumab.
-
Prescription medicine decision summarySteqeyma (ustekinumab) has been approved to treat moderate to severe plaque psoriasis, active psoriatic arthritis, crohn's disease, and ulcerative colitis
-
Prescription medicine registrationActive ingredients: Ustekinumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 100 mg/ 4 mL solution for intravenous infusion, vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEGZELMA bevacizumab 400 mg/ 16 mL solution for intravenous infusion, vial.